Discovery of the First-in-Class G9a/GLP Covalent Inhibitors-Reference-Cited by-同舟云学术

Discovery of the First-in-Class G9a/GLP Covalent Inhibitors

Published:2022-06-28 Issue:15 Volume:65 Page:10506-10522
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Park Kwang-Su¹,Xiong Yan¹,Yim Hyerin¹,Velez Julia¹,Babault Nicolas¹,Kumar Prashasti¹,Liu Jing¹,Jin Jian¹^ORCID

Affiliation:

1. Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences, Oncological Sciences and Neuroscience, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States

Funder

Icahn School of Medicine at Mount Sinai

Eunice Kennedy Shriver National Institute of Child Health and Human Development

Levo Therapeutics

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.2c00652

Reference68 articles.

1. Histone lysine methyltransferases in biology and disease

2. Histone Lysine Methylation Dynamics: Establishment, Regulation, and Biological Impact

3. Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease

4. Critical roles of non-histone protein lysine methylation in human tumorigenesis

5. Emerging roles of lysine methylation on non-histone proteins

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advanced technologies for screening and identifying covalent inhibitors;TrAC Trends in Analytical Chemistry;2024-09

2. Newly developed oral bioavailable EHMT2 inhibitor as a potential epigenetic therapy for Prader-Willi syndrome;Molecular Therapy;2024-08

3. Discovery of Potent and Selective G9a Degraders for the Treatment of Pancreatic Cancer;Journal of Medicinal Chemistry;2024-07-23

4. Discovery of a Highly Potent Lysine Methyltransferases G9a/NSD2 Dual Inhibitor to Treat Solid Tumors;Journal of Medicinal Chemistry;2024-07-15

5. Discovery of the First-in-Class G9a/GLP PROTAC Degrader;Journal of Medicinal Chemistry;2024-04-11